FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Yves Fradet

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Co-author Network

Publications

TOP 3
Éric Lévesque; Mélanie Rouleau; Chia-Cheng Yu; Étienne Audet-Walsh; Bo-Ying Bao; Patrick Caron; Yves Fradet; Chao-Yuan Huang; Shu-Pin Huang; Louis Lacombe; Isabelle Laverdière; Chantal Guillemette
Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.
Étienne Audet-Walsh; Judith Bellemare; Pierre Douville; Vincent Fradet; Yves Fradet; Chantal Guillemette; Louis Lacombe; Eric Lévesque
The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy.
Yves Fradet
Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: pro.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Yves Fradet (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Éric Lévesque; Mélanie Rouleau; Chia-Cheng Yu; Étienne Audet-Walsh; Bo-Ying Bao; Patrick Caron; Yves Fradet; Chao-Yuan Huang; Shu-Pin Huang; Louis Lacombe; Isabelle Laverdière; Chantal Guillemette
Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(3):699-709.
2012: Étienne Audet-Walsh; Judith Bellemare; Pierre Douville; Vincent Fradet; Yves Fradet; Chantal Guillemette; Louis Lacombe; Eric Lévesque
The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy.
European urology 2012;62(1):88-96.
2012: Yves Fradet
Cost-effectiveness of fluorescent cystoscopy for noninvasive papillary tumors: pro.
The Journal of urology 2012;187(5):1537-9.
2011: Etienne Audet-Walsh; Bo-Ying Bao; Judith Bellemare; Pierre Douville; Vincent Fradet; Yves Fradet; Hugo Girard; Chantal Guillemette; Shu-Pin Huang; Louis Lacombe; Geneviève Nadeau; Eric Lévesque
SRD5A polymorphisms and biochemical failure after radical prostatectomy.
European urology 2011;60(6):1226-34.
2011: Daniel J Sargent; Qian Shi; Gary O Siemons; Tsung-Teh Wu; Guillaume Beaudry; Brian M Bot; Thomas Clancy; Sharlene Gill; Atoussa Goldar-Najafi; Jean-François Haince; Michael O Meyers; Murray B Resnick; Yves Fradet
Evaluation of guanylyl cyclase C lymph node status for colon cancer staging and prognosis.
Annals of surgical oncology 2011;18(12):3261-70.
2011: Geneviève Nadeau; Étienne Audet-Walsh; Bo-Ying Bao; Judith Bellemare; Patrick Caron; Pierre Douville; Christine Flageole; Yves Fradet; Chantal Guillemette; Shu-Pin Huang; Louis Lacombe; Eric Lévesque
Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer.
The Journal of clinical endocrinology and metabolism 2011;96(9):E1550-7.
2011: Anis Aziz; Yves Fradet; Hélène Hovington; Hélène LaRue; Eva Latulippe; Annie Lessard; Katherine Moore; Louis Lacombe
Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2.
BJU international 2011;108(4):531-7.
2011: Cherifa Ayari; Alain Bergeron; Hélène LaRue; Claire Ménard; Yves Fradet
Toll-like receptors in normal and malignant human bladders.
The Journal of urology 2011;185(5):1915-21.
2010: Dominique Trudel; Yves Fradet; François Meyer; Bernard Têtu
Matrix metalloproteinase 9 is associated with Gleason score in prostate cancer but not with prognosis.
Human pathology 2010;41(12):1694-701.
2010: Michele Lodde; Louis Lacombe; Yves Fradet
Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
Urology 2010;76(5):1189-93.
2009: Alain Bergeron; Valérie Picard; Hélène LaRue; François Harel; Hélène Hovington; Louis Lacombe; Yves Fradet
High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer.
International journal of cancer. Journal international du cancer 2009;125(6):1365-71.
2009: Yves Fradet; Laurence Klotz; John Trachtenberg; Alexandre Zlotta
The burden of prostate cancer in Canada.
Canadian Urological Association journal = Journal de l'Association des urologues du Canada 2009;3(3 Suppl 2):S92-S100.
2009: Cherifa Ayari; Hélène LaRue; Hélène Hovington; Marc Decobert; François Harel; Alain Bergeron; Bernard Têtu; Louis Lacombe; Yves Fradet
Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
European urology 2009;55(6):1386-95.
2009: Yves Fradet
Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
Current opinion in urology 2009;19(3):243-6.
2008: Michele Lodde; Yves Fradet
The detection of genetic markers of bladder cancer in urine and serum.
Current opinion in urology 2008;18(5):499-503.
2008: Marc Decobert; Hélène LaRue; François Harel; François Meyer; Yves Fradet; Louis Lacombe
Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?
Cancer 2008;113(4):710-6.
2008: Yves Fradet
The management of high-risk prostate cancer in 2008.
World journal of urology 2008;26(3):203.
2008: Dominique Trudel; Yves Fradet; François Meyer; François Harel; Bernard Têtu
Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry.
Human pathology 2008;39(5):731-9.
2008: Geneviève Patry; Hélène Hovington; Hélène LaRue; François Harel; Yves Fradet; Louis Lacombe
Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
International journal of cancer. Journal international du cancer 2008;122(7):1592-7.
2007: Ion Popa; Yves Fradet; Geneviève Beaudry; Hélène Hovington; Guillaume Beaudry; Bernard Têtu
Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2007;20(11):1121-7.
2007: Yves Fradet
Rebuttal: Should Canadians be offered systematic prostate cancer screening? YES.
Canadian family physician Médecin de famille canadien 2007;53(7):1140-3.
2007: Valérie Picard; Alain Bergeron; Hélène LaRue; Yves Fradet
MAGE-A9 mRNA and protein expression in bladder cancer.
International journal of cancer. Journal international du cancer 2007;120(10):2170-7.
2007: Brant A Inman; Thomas J Sebo; Xavier Frigola; Haidong Dong; Erik J Bergstralh; Igor Frank; Yves Fradet; Louis Lacombe; Eugene D Kwon
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Cancer 2007;109(8):1499-505.
2006: François Meyer; Bernard Têtu; Isabelle Bairati; Louis Lacombe; Yves Fradet
Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer.
The Canadian journal of urology 2006;13(5):3255-60.
2006: Yves Fradet; Valérie Picard; Alain Bergeron; Hélène LaRue
Cancer-testis antigen expression in bladder cancer.
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2006;16(4):421-8.
2006: Yves Fradet; Armen G Aprikian; George Dranitsaris; Robert Siemens; John Tsihlias; Neil Fleshner
Does prolonging the time to bladder cancer surgery affect long-term cancer control: a systematic review of the literature.
The Canadian journal of urology 2006;13 Suppl 3():37-47.
2006: Marc Decobert; Hélène LaRue; Alain Bergeron; François Harel; Christian Pfister; Francois Rousseau; Louis Lacombe; Yves Fradet
Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
The Journal of urology 2006;175(4):1506-11.
2005: Yves Fradet; Valérie Picard; Alain Bergeron; Hélène LaRue
Cancer-testis antigen expression in bladder cancer.
Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie 2005;15(6 Suppl 1):1303-13.
2005: Séverine Hervouet; Josée Savard; Sébastien Simard; Hans Ivers; Jacques Laverdière; Eric Vigneault; Yves Fradet; Louis Lacombe
Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery.
Journal of pain and symptom management 2005;30(5):474-84.
2005: Brant A Inman; François Harel; Jean-François Audet; François Meyer; Pierre Douville; Yves Fradet; Louis Lacombe
Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival.
European urology 2005;47(5):695-702.
2005: Josée Savard; Sébastien Simard; Séverine Hervouet; Hans Ivers; Louis Lacombe; Yves Fradet
Insomnia in men treated with radical prostatectomy for prostate cancer.
Psycho-oncology 2005;14(2):147-56.
2005: Bernard Têtu; Rabi Tiguert; François Harel; Yves Fradet
ImmunoCyt/uCyt+ improves the sensitivity of urine cytology in patients followed for urothelial carcinoma.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2005;18(1):83-9.
2004: Sahar Hamed; Hélène LaRue; Hélène Hovington; Johanne Girard; Lucie Jeannotte; Eva Latulippe; Yves Fradet
Accelerated induction of bladder cancer in patched heterozygous mutant mice.
Cancer research 2004;64(6):1938-42.
2004: Jérôme Rigaud; Rabi Tiguert; Marc Decobert; Hélène Hovington; Eva Latulippe; Jacques Laverdiere; Hélène LaRue; Louis Lacombe; Yves Fradet
Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.
The Prostate 2004;58(3):269-76.
2003: Dominique Trudel; Yves Fradet; François Meyer; François Harel; Bernard Têtu
Significance of MMP-2 expression in prostate cancer: an immunohistochemical study.
Cancer research 2003;63(23):8511-5.
2003: Brant A Inman; François Harel; Rabi Tiguert; Louis Lacombe; Yves Fradet
Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients.
The Journal of urology 2003;170(5):1888-91.
2003: Hélène LaRue; Maryse Simoneau; Tahar O Aboulkassim; Patricia Lemieux; Johanne Girard; Sahar Hamed; Hélène Hovington; Lucie Jeannotte; Yves Fradet
[The PATCHED/Sonic Hedgehog signalling pathway in superficial bladder cancer].
Médecine sciences : M/S 2003;19(10):920-5.
2003: Rabi Tiguert; Jérôme Rigaud; Louis Lacombe; Jacques Laverdière; Yves Fradet
Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
The Journal of urology 2003;170(2 Pt 1):447-50.
2003: Tahar O Aboulkassim; Hélène LaRue; Patricia Lemieux; Francois Rousseau; Yves Fradet
Alteration of the PATCHED locus in superficial bladder cancer.
Oncogene 2003;22(19):2967-71.
2002: Rabi Tiguert; Annie Lessard; Alan So; Yves Fradet
Prognostic markers in muscle invasive bladder cancer.
World journal of urology 2002;20(3):190-5.
2002: Mireille Grégoire; Frédéric Liandier; Alain Naud; Louis Lacombe; Yves Fradet
Does the potassium stimulation test predict cystometric, cystoscopic outcome in interstitial cystitis?
The Journal of urology 2002;168(2):556-7.
2002: Yves Fradet
Role of radical prostatectomy in high-risk prostate cancer.
The Canadian journal of urology 2002;9 Suppl 1():8-13.
2002: Rabi Tiguert; Yves Fradet
New diagnostic and prognostic tools in bladder cancer.
Current opinion in urology 2002;12(3):239-43.
2001: F Meyer; Isabelle Bairati; C Bédard; Louis Lacombe; Bernard Têtu; Yves Fradet
Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
Urology 2001;58(2 Suppl 1):71-7.
2001: Louis Lacombe; A Maillette; François Meyer; C Veilleux; Lynne Moore; Yves Fradet
Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy.
International journal of cancer. Journal international du cancer 2001;95(3):135-9.
2000: Maryse Simoneau; Hélène LaRue; Tahar O Aboulkassim; François Meyer; Lynne Moore; Yves Fradet
Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest.
Oncogene 2000;19(54):6317-23.
2000: Isabelle Bairati; R Larouche; François Meyer; Lynne Moore; Yves Fradet
Lifetime occupational physical activity and incidental prostate cancer (Canada).
Cancer causes & control : CCC 2000;11(8):759-64.
2000: Yves Fradet; Louis Lacombe
Can biological markers predict recurrence and progression of superficial bladder cancer?
Current opinion in urology 2000;10(5):441-5.
2000: C Pfister; Hélène LaRue; Lynne Moore; Louis Lacombe; C Veilleux; B Tetu; François Meyer; Yves Fradet
Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.
International journal of cancer. Journal international du cancer 2000;89(1):100-4.
2000: Hélène LaRue; P Allard; Maryse Simoneau; C Normand; C Pfister; Lynne Moore; François Meyer; Bernard Têtu; Yves Fradet
P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers.
Carcinogenesis 2000;21(1):101-6.
1999: C Pfister; Lynne Moore; P Allard; Hélène LaRue; Louis Lacombe; Bernard Têtu; François Meyer; Yves Fradet
Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4079-84.
1999: F Meyer; L Moore; Isabelle Bairati; Louis Lacombe; Bernard Têtu; Yves Fradet
Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure.
The Journal of urology 1999;162(6):2024-8.
1999: C Pfister; Louis Lacombe; M C Vezina; Lynne Moore; Hélène LaRue; Bernard Têtu; François Meyer; Yves Fradet
Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors.
Human pathology 1999;30(11):1350-5.
1999: François Meyer; Isabelle Bairati; Ramak Shadmani; Yves Fradet; Lynne Moore
Dietary fat and prostate cancer survival.
Cancer causes & control : CCC 1999;10(4):245-51.
1999: Maryse Simoneau; Hélène LaRue; Yves Fradet
Low frequency of human papillomavirus infection in initial papillary bladder tumors.
Urological research 1999;27(3):180-4.
1999: F Meyer; L Moore; Isabelle Bairati; Yves Fradet
Downward trend in prostate cancer mortality in Quebec and Canada.
The Journal of urology 1999;161(4):1189-91.
1999: Maryse Simoneau; Tahar O Aboulkassim; Hélène LaRue; Francois Rousseau; Yves Fradet
Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31.
Oncogene 1999;18(1):157-63.
1999: Yves Fradet; François Meyer; Isabelle Bairati; Ramak Shadmani; L Moore
Dietary fat and prostate cancer progression and survival.
European urology 1999;35(5-6):388-91.
1998: François Meyer; Lynne Moore; Isabelle Bairati; Yves Fradet
Quebec prostate cancer mortality dropped in 1996.
Cancer prevention & control : CPC = Prévention & contrôle en cancérologie : PCC 1998;2(4):163-6.
1998: Isabelle Bairati; F Meyer; Yves Fradet; L Moore
Dietary fat and advanced prostate cancer.
The Journal of urology 1998;159(4):1271-5.
1998: Yves Fradet
Phenotypic characterization of bladder cancer.
European urology 1998;33 Suppl 4():5-6.
1997: Hélène LaRue; C Parent-Vaugeois; Alain Bergeron; Serge Champetier; Yves Fradet
Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer.
International journal of cancer. Journal international du cancer 1997;71(6):986-92.
1997: Harry W Herr; Yves Fradet; F A Klein
Summary of effect of intravesical bacillus Calmette-Guerin (BCG) on carcinoma in situ of the bladder (by Harry W. Herr, MD, Carl M. Pinsky, MD, Willet F. Whitmore, Jr, MD, Herbert F. Oettgen, MD, and Myron R. Melamed, MD). 1983.
Seminars in urologic oncology 1997;15(2):80-5.
1997: Mireille Grégoire; Yves Fradet; F Meyer; B Têtu; R Bois; G Bédard; R Charrois; A Naud
Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors.
The Journal of urology 1997;157(5):1660-4.
1997: Alain Bergeron; Hélène LaRue; Yves Fradet
Biochemical analysis of a bladder-cancer-associated mucin: structural features and epitope characterization.
The Biochemical journal 1997;321 ( Pt 3)():889-95.
1997: François Meyer; Isabelle Bairati; Yves Fradet; L Moore
Dietary energy and nutrients in relation to preclinical prostate cancer.
Nutrition and cancer 1997;29(2):120-6.
1996: Alain Bergeron; Serge Champetier; Hélène LaRue; Yves Fradet
MAUB is a new mucin antigen associated with bladder cancer.
The Journal of biological chemistry 1996;271(12):6933-40.
1996: Alain Bergeron; Hélène LaRue; Yves Fradet
Identification of a superficial bladder tumor-associated glycoform of the carcinoembryonic antigen by monoclonal antibody 19A211.
Cancer research 1996;56(4):908-15.
1990: Yves Fradet; Hélène LaRue; C Parent-Vaugeois; Alain Bergeron; C Dufour; L Boucher; L Bernier
Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas.
International journal of cancer. Journal international du cancer 1990;46(6):990-7.